This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
NEJM is pleased to participate in an innovative new service from CCC that aligns with our goal to meet the information needs of researchers for the highest quality studies in medicalscience,” said Rob McKinney, Director, NEJM Group Licensing. NEJM is recognized as the world’s leading medical journal and website.
In this Q&A, Dr Imran Khan, PhD, Vice President Medical Affairs, Hematology at Johnson & Johnson Innovative Medicine, highlights the current landscape of CAR T therapies such as CARVYKTI and touches on the future direction of the sector. Most recently, Imran has served as MedicalScience Liaison (MSL) Head, Oncology U.S.
The use of behavioral data and adult digital learning principles is a potent advance in medicine as it allows for the technology to crystalize when, where, and how learning can take place and create greater bonds between clinicians and the content they view or are exposed to. Reference: 1. Griebenow R, Herrmann H, Smith M, et al.
The primary purpose of MedicalScience Liaison MSL is to establish and maintain peer-peer relationships with leading physicians, referred to as Key Opinion Leaders KOL’s, at major academic institutions and clinics. We have highlighted 5 quick tips for MSL to aid them through the process when engaging with KOL’s.
The pharmaceutical community has reached somewhat of a turning point as it commercialises a growing number of speciality medicines relying on complex new treatment pathways. As with many aspects of the medical world, they are now shifting online. With this comes new hope for previously underserved patient populations. A fresh approach.
An alpha particle, consisting of two protons and two neutrons bound together and akin to a helium-4 nucleus, is much trickier to work with in medicine because it is extremely powerful, yet has a very short effective range. Kelson then turned his sights on medicine, together with co-inventor Prof.
He provides a fascinating glimpse into what it takes to excel in the field of medical device sales, emphasizing the importance of authenticity and passion. The perfect blend of persistent dedication, a heartwarming touch of southern hospitality, and an innate understanding of the needs of both physicians and patients. I find Dr. B.
Medicalscience Liaisons know that change is coming; How are they cashing in? Medicalscience liaisons (MSLs) within pharmaceutical companies deal in a special currency: scientific exchange and real-world insights gathering.
In today’s quality-driven environment, HCPs and population health managers are focused on achieving specific quality metrics to provide evidence-based medicine as well as receive incentive payments associated with achieving them. Advance MedicalScience.
They will be located in a specific geographical location, but it is likely that they will specialize in certain products or medical areas. They are medical agents (i.e., supplier agents) and are responsible for marketing and selling medical products and services to healthcare professionals.
In the end, I decided to become an engineer but from the get-go specialized in medical technology. They allowed me to do some classes in medicalscience, which was very nice. I got going from the get-go in medical technology. The whole story came to light in a backward way and this happens often in medicine.
Hait , Executive VP, Chief External Innovation and Chief Medical Officer, Johnson & Johnson , a renowned physician-scientist and Treasurer of the American Association for Cancer Research engaged in a thought-provoking discussion on the evolving landscape of cancer research and treatment. Dr. William N.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content